Meftal advisory: Commission warns of likely adverse drug reactions

The Indian Pharmacopoeia Commission (IPC) has issued a drug-safety alert for healthcare professionals and patients to monitor the adverse reactions of the painkiller Meftal, commonly used for menstrual cramps and rheumatoid arthritis. The commission stated that a preliminary analysis of adverse drug reactions revealed drug reactions with eosinophilia and systemic symptoms (DRESS) syndrome.